MENLO PARK, Calif.,
Jan. 4, 2018 /PRNewswire/ -- Sight
Sciences, Inc., a venture-backed, commercial stage ophthalmic
device company, today announced U.S. Food and Drug Administration
(FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical
tool dually indicated for the delivery of controlled volumes of
viscoelastic fluid as well as the cutting of trabecular meshwork
tissue. In addition, the company announced three key hires who
possess proven leadership capabilities and industry experience to
advance the commercial strategy and build out its senior leadership
The OMNI System is a next-generation technology that combines
two distinct functions into one device: (1) controlled viscoelastic
delivery anywhere within the anterior segment, including in up to
360 degrees of Schlemm's canal; and (2) controlled, customizable
trabeculotomy. Each of these canal procedures is sufficiently
established to have its own Category 1 CPT code, and the OMNI
System can be used on a standalone basis or in conjunction with
"The OMNI System is uniquely designed to target both sources of
resistance in the conventional outflow pathway with a single
integrated device," said Nathan
Radcliffe, MD, Microincisional Surgery Center of Excellence
of New York Eye and Ear Infirmary. "It offers a new, sophisticated
solution for two well-established procedures, canaloplasty and
trabeculotomy. It will be a welcome and exciting addition to my
"This is a major milestone for Sight Sciences and further
expands our portfolio of solutions for ophthalmologists performing
angle surgery," said Shawn O'Neil,
Sr. Vice President of Sales and Marketing at Sight Sciences.
"Our R&D team designed the OMNI System based on feedback from
our customers, and we are excited to bring this innovative,
multi-procedure technology to the surgical glaucoma market."
Sight Sciences also announced three key hires who have joined
O'Neil to establish the company's commercial leadership team.
Patrick Smale joined as Vice
President of Marketing, Surgical Glaucoma, Jeff Francis joined as Vice President of Sales,
Surgical Glaucoma and Todd Love
joined as Vice President of Marketing, Dry Eye. The commercial
leadership team has already started hiring marketing talent and
sales professionals to build out and execute the company's
Patrick Smale will lead the
marketing program for Sight Sciences' surgical portfolio, which
includes the OMNI System. Most recently, Smale was Global Product
Director, Surgical Glaucoma at Alcon Laboratories, a global leader
in ophthalmology, where he was responsible for the global launch of
the CyPass Micro-stent. Prior, he held positions of increasing
responsibility and leadership in market research and business
analytics for over 10 years at Alcon covering the pharmaceutical,
surgical and vision care businesses.
Jeff Francis will build and lead
the sales force for Sight Sciences' surgical devices. Francis
brings nearly 20 years of experience in the pharmaceutical, medical
device and surgical arenas. He joined Sight Sciences from Nestle
Skin Health, and prior to that, Alcon, where he began his career
and held positions of increasing responsibility in sales training,
sales leadership, marketing and hospital/corporate accounts.
Todd Love will lead the marketing
program for Sight Sciences' dry eye product portfolio. Love joined
Sight Sciences from Bausch + Lomb where he was Director,
Professional Strategy and led the development of key opinion
leaders, optometric institutions and professional programs. Prior,
Love held positions of increasing responsibility at Alcon in market
development, global marketing and brand management where he led the
company's global contact lens care franchise.
"We are pleased that Patrick, Jeff and Todd have joined our
commercial team to advance development and launch efforts for our
surgical glaucoma and dry eye product portfolios," said
Paul Badawi, CEO of Sight Sciences.
"Our core commercial leadership team now holds more than 70 years
of collective experience in commercial excellence in the
ophthalmology and optometry spaces and is poised to lead Sight
Sciences' strategic objectives."
About Sight Sciences
Sight Sciences is a medical device company dedicated to the
development of intelligently designed and engineered products that
address the underlying physiology of ophthalmic diseases. The
company operates two business lines: surgical and non-surgical
devices. Its surgical product portfolio consists of the VISCO360®,
TRAB®360 and OMNI™ surgical devices. Its non-surgical product
portfolio consists of technologies in the advanced stages of
development for dry eye disease.
SOURCE Sight Sciences, Inc.